BIOMAT Database Logo BIOMAT Database Logo

In vitro antibacterial activity of sulbactam-durlobactam in combination with other antimicrobial agents against Acinetobacter baumannii-calcoaceticus complex. 2024

Sarah M McLeod, and Nicole M Carter, and Patricia A Bradford, and Alita A Miller
Entasis Therapeutics Inc., an affiliate of Innoviva Specialty Therapeutics, Inc., Waltham, MA, USA. Electronic address: Sarah.McLeod@istx.com.

Combinations of the β-lactam/β-lactamase inhibitor sulbactam-durlobactam and seventeen antimicrobial agents were tested against strains of Acinetobacter baumannii in checkerboard assays. Most combinations resulted in indifference with no instances of antagonism. These results suggest sulbactam-durlobactam antibacterial activity against A. baumannii is unlikely to be affected if co-dosed with other antimicrobial agents.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000151 Acinetobacter Infections Infections with bacteria of the genus ACINETOBACTER. Mimae Infections,Infections, Acinetobacter,Infections, Mimae,Acinetobacter Infection,Infection, Acinetobacter,Infection, Mimae,Mimae Infection
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D013407 Sulbactam A beta-lactamase inhibitor with very weak antibacterial action. The compound prevents antibiotic destruction of beta-lactam antibiotics by inhibiting beta-lactamases, thus extending their spectrum activity. Combinations of sulbactam with beta-lactam antibiotics have been used successfully for the therapy of infections caused by organisms resistant to the antibiotic alone. Bétamaze,CP-45899,Combactam,Penicillanic Acid Sulfone,Sulbactam Sodium,CP 45899,CP45899,Sodium, Sulbactam,Sulfone, Penicillanic Acid
D016954 Acinetobacter calcoaceticus A species of gram-negative, aerobic bacteria found in soil and water. Although considered to be normally nonpathogenic, this bacterium is a causative agent of nosocomial infections, particularly in debilitated individuals. Micrococcus calcoaceticus,Moraxella calcoacetica,Neisseria winogradskyi
D053961 Azabicyclo Compounds Bicyclic bridged compounds that contain a nitrogen which has three bonds. The nomenclature indicates the number of atoms in each path around the rings, such as [2.2.2] for three equal length paths. Some members are TROPANES and BETA LACTAMS. Azabicyclo(1.1.0)Butanes,Azabicyclo(2.2.2)Octanes,Azabicyclo(3.3.1)Nonanes,Azabicyclo(4.3.0)Nonanes,Azabicyclo(5.2.2)Undecanes
D040981 Acinetobacter baumannii A species of gram-negative, aerobic bacteria, commonly found in the clinical laboratory, and frequently resistant to common antibiotics. Bacterium anitratum
D065093 beta-Lactamase Inhibitors Endogenous substances and drugs that inhibit or block the activity of BETA-LACTAMASES. beta Lactamase Inhibitor,beta Lactamase Inhibitors,beta-Lactamase Inhibitor,beta Lactamase Antagonists,Antagonists, beta Lactamase,Inhibitor, beta Lactamase,Inhibitor, beta-Lactamase,Inhibitors, beta Lactamase,Inhibitors, beta-Lactamase,Lactamase Antagonists, beta,Lactamase Inhibitor, beta,Lactamase Inhibitors, beta

Related Publications

Sarah M McLeod, and Nicole M Carter, and Patricia A Bradford, and Alita A Miller
n vitro pharmacokinetics/pharmacodynamics of the β-lactamase inhibitor, durlobactam, in combination with sulbactam against Acinetobacter baumannii-calcoaceticus complex.
January 2024, Antimicrobial agents and chemotherapy,
Sarah M McLeod, and Nicole M Carter, and Patricia A Bradford, and Alita A Miller
Sulbactam-durlobactam for infections caused by Acinetobacter baumannii-calcoaceticus complex.
August 2023, The Lancet. Infectious diseases,
Sarah M McLeod, and Nicole M Carter, and Patricia A Bradford, and Alita A Miller
In Vitro Activity of Sulbactam-Durlobactam against Acinetobacter baumannii-calcoaceticus Complex Isolates Collected Globally in 2016 and 2017.
March 2020, Antimicrobial agents and chemotherapy,
Sarah M McLeod, and Nicole M Carter, and Patricia A Bradford, and Alita A Miller
In Vitro Activity of Sulbactam-Durlobactam against Global Isolates of Acinetobacter baumannii-calcoaceticus Complex Collected from 2016 to 2021.
September 2022, Antimicrobial agents and chemotherapy,
Sarah M McLeod, and Nicole M Carter, and Patricia A Bradford, and Alita A Miller
Sulbactam-durlobactam for infections caused by Acinetobacter baumannii-calcoaceticus complex - Authors' reply.
August 2023, The Lancet. Infectious diseases,
Sarah M McLeod, and Nicole M Carter, and Patricia A Bradford, and Alita A Miller
In vivo dose response and efficacy of the β-lactamase inhibitor, durlobactam, in combination with sulbactam against the Acinetobacter baumannii-calcoaceticus complex.
January 2024, Antimicrobial agents and chemotherapy,
Sarah M McLeod, and Nicole M Carter, and Patricia A Bradford, and Alita A Miller
In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii.
September 2020, The Journal of antimicrobial chemotherapy,
Sarah M McLeod, and Nicole M Carter, and Patricia A Bradford, and Alita A Miller
The Pharmacokinetics/Pharmacodynamic Relationship of Durlobactam in Combination With Sulbactam in In Vitro and In Vivo Infection Model Systems Versus Acinetobacter baumannii-calcoaceticus Complex.
May 2023, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Sarah M McLeod, and Nicole M Carter, and Patricia A Bradford, and Alita A Miller
In vitro activity of sulbactam/durlobactam against clinical isolates of Acinetobacter baumannii collected in China.
July 2020, The Journal of antimicrobial chemotherapy,
Sarah M McLeod, and Nicole M Carter, and Patricia A Bradford, and Alita A Miller
In vitro activity of antimicrobial agents against Acinetobacter calcoaceticus.
January 1986, Drugs under experimental and clinical research,
Copied contents to your clipboard!